Postvaccination immune-mediated hepatitis: what do we really know?

Lasagna, Angioletta; Pedrazzoli, Paolo; Bruno, Raffaele; Sacchi, Paolo

doi:10.2217/imt-2023-0038

Cited by 2 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No immune-mediated adverse events have been reported, unlike other types of vaccines. 17 , 18 However, it is important to note that the number of patients involved in this study was too small to make any conclusive statements. During the counseling, it is crucial to reassure the patients based on about the safety of the vaccine.…”

Section: Discussionmentioning

confidence: 92%

The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy

Lasagna,

Mele,

Bergami

et al. 2023

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

Herpes zoster (HZ) is caused by the reactivation of latent varicella zoster virus (VZV). Severe immunocompromising conditions, such as solid tumors, have been largely associated with an increased risk for HZ due to waning VZV-specific cellular immunity. With the approval of the adjuvanted glycoprotein E (gE)-based recombinant vaccine (RZV; Shingrix™, GSK) also in immunocompromised subjects, HZ is considered a vaccine-preventable disease changing perspectives in immunocompromised subjects. To date, no clinical trial has evaluated the immunogenicity in the patients with cancer undergoing immunotherapy. In this study, we describe the humoral and cell-mediated immune responses in 38 cancer patients treated with immune checkpoint inhibitors (ICIs) and receiving RZV. We used samples collected at baseline (T0), 3 weeks (T2), and 6 months (T3) after the complete RV vaccination schedule. Our data showed that a significant proportion (40,5%) of RZV recipients mounted a stronger humoral and cell-mediated immune response at 3 weeks (T2) after complete RZV vaccination schedule. Interestingly, both humoral and cell-mediated immune responses were mostly stable over 6 months (T3). Interestingly, the overall IFNγ-producing lymphocytes was mainly associated with CD4 T cell response ( p = .0012). In conclusion, data from our pilot study suggest a strong and long-lasting immunogenicity of RZV in ICI-treated patients. Prospective analyses at 1 year after vaccination will be performed in order to evaluate the long-term persistence of humoral and cell-mediated response against RZV.

show abstract

Section: Discussionmentioning

confidence: 92%

The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy

Lasagna,

Mele,

Bergami

et al. 2023

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some case reports described immune-mediated vaccine-associated adverse events such as hepatitis, 21 but we have to consider that these immunemediated mechanisms can also be caused by the viral infections themselves and that vaccines are indispensable to minimise these risks. 22 In the third part of the survey, we investigated which vaccines patients with cancer typically receive, as estimated by the oncologists. The full course of anti-SARS-CoV-2 and anti-seasonal flu are the most widely administered vaccines, while less than half of the patients received the pneumococcal or anti-meningococcal vaccine.…”

Section: Discussionmentioning

confidence: 99%

“…Some case reports described immune-mediated vaccine-associated adverse events such as hepatitis, 21 but we have to consider that these immune-mediated mechanisms can also be caused by the viral infections themselves and that vaccines are indispensable to minimise these risks. 22 …”

Section: Discussionmentioning

confidence: 99%

Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology

Lasagna

Brunello

Silvestris

et al. 2023

Tumori

Self Cite

View full text Add to dashboard Cite

Background: Patients with cancer present a higher risk of vaccine-preventable diseases. Recommended vaccinations are the most cost-effective measure to reduce the risk of transmission and related complications. Nevertheless, vaccination rates are inadequate. Oncologists have a central role in tailored vaccine communication to their patients. We present the results of a survey conducted by AIOM in 2022, focusing on the perception of the problem by oncologists. Materials and Methods: An anonymous 31-item online questionnaire was shared on 15 September 2022 on the AIOM website. The objectives of this survey were to examine the perception of Italian oncologists on vaccine-preventable diseases and the main available vaccines, their attitude towards recommending vaccines and the COVID-19 pandemic impact on their habits regarding vaccine-preventable diseases. Results: Between September 2022 and January 2023, 114 medical oncologists (5% of the members) completed the anonymous questionnaire. At the first oncological visit, only 30% of respondents usually propose a vaccination schedule to all their patient, 41% do not usually discuss vaccinations at the first visit and 29% recommend vaccines exclusively to specific categories of patients. For 56% of respondents, patients are more aware of the benefits of vaccines, whereas 36% reported that patients are worried of receiving too many vaccines. Conclusion: This is the first survey conducted among Italian oncologists to better understand the perception and attitudes towards the vaccination. It highlights the urgent issues of educating and training oncologists in vaccine-preventable diseases and vaccine awareness and the need to build (or implement) a network of multidisciplinary collaborations.

show abstract

Postvaccination immune-mediated hepatitis: what do we really know?

Abstract: Tweetable abstract The percentage of patients with immune-mediated vaccine-associated hepatitis is minimal compared with the number of patients vaccinated worldwide.

Cited by 2 publications

References 20 publications

The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy

The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy

Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology

Contact Info

Product

Resources

About